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Abstract
Background: The ORISCAV-LUX study is the first baseline survey of an on-going cardiovascular health monitoring
programme in Grand-Duchy of Luxembourg. The main objectives of the present manuscript were 1) to describe
the study design and conduct, and 2) to present the salient outcomes of the study, in particular the prevalence of
the potentially modifiable and treatable cardiovascular disease risk factors in the adult population residing in
Luxembourg.
Method: ORISCAV-LUX is a cross-sectional study based on a random sample of 4496 subjects, stratified by gender,
age categories and district, drawn from the national insurance registry of 18-69 years aged Luxembourg residents,
assuming a response rate of 30% and a proportion of 5% of institutionalized subjects in each stratum. The
cardiovascular health status was assessed by means of a self-administered questionnaire, clinical and
anthropometric measures, as well as by blood, urine and hair examinations. The potentially modifiable and
treatable risk factors studied included smoking, hypertension, dyslipidemia, diabetes mellitus, and obesity. Both
univariate and multivariate statistical analyses used weighted methods to account for the stratified sampling
scheme.
Results: A total of 1432 subjects took part in the survey, yielding a participation rate of 32.2%. This figure is higher
than the minimal sample size of 1285 subjects as estimated by power calculation. The most predominant
cardiovascular risk factors were dyslipidemia (69.9%), hypertension (34.5%), smoking (22.3%), and obesity (20.9%),
while diabetes amounted 4.4%. All prevalence rates increased with age (except smoking) with marked gender
differences (except diabetes). There was a significant difference in the prevalence of hypertension and of lipid
disorders by geographic region of birth. The proportion of subjects cumulating two or more cardiovascular risk
factors increased remarkably with age and was more predominant in men than in women (P<0.0001). Only 14.7%
of men and 23.1% of women were free of any cardiovascular risk factor. High prevalence of non-treated CVRF,
notably for hypertension and dyslipidemia, were observed in the study population.
Conclusion: The population-based ORISCAV-LUX survey revealed a high prevalence of potentially modifiable and
treatable cardiovascular risk factors among apparently healthy subjects; significant gender and age-specific
differences were seen not only for single but also for combined risk factors. From a public health perspective,
these preliminary findings stress the urgent need for early routine health examinations, preventive interventions
and lifestyle behavioural changes, even in young asymptomatic adults, to decrease cardiovascular morbidity and
mortality in Luxembourg.
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Today around 60% of worldwide deaths and 43% of the
global burden of diseases are attributed to coronary
heart disease, stroke and type 2 diabetes mellitus[1].
These diseases are predicted to account for 73% of glo-
bal deaths and 60% of the global burden by year 2020
[2]. There is strong evidence that cigarette smoking,
obesity, lipid disorders, elevated blood pressure and dia-
betes mellitus are not only associated with each other
[3-5] but also with cardiovascular morbidity and mortal-
ity[6-14]. On the other hand, it has been shown that
major changes in the risk of CVD can be reduced by
modifications of the lifestyle and social behaviour of
individuals [15,16]. Despite major advances in preven-
tion, diagnosis and treatment measures, cardiovascular
disease (CVD) is still the main cause of mortality in Eur-
ope. It accounts for over 4 million deaths yearly, i.e.,
nearly half (49%) of all European deaths, but with strik-
ing geographical variations[17].
The Grand-Duchy of Luxembourg is a small country
in the heart of Europe landlocked by Belgium, France
and Germany, with a population of 493,500 inhabitants
(official estimate, 2009) over an area of about 2600 km
2.
Distinctively, Luxembourg country is a multicultural
society. Luxembourgish people constitute approximately
56.3% of the population, while 43.7% of the inhabitants
are well-integrated foreign residents from over 150 dif-
ferent nationalities, mostly Portuguese (16.2%), French
(5.8%), Italians (3.9%) and Belgians (3.4%). Evidently, the
national health profile is significantly determined by the
health of its immigrants.
In Luxembourg, cardiovascular mortality accounted
for about one-third of total causes of death in 2005[18].
According to a recent study comparing the cardiovascu-
lar mortality rates in three neighbouring regions, Grand-
Duchy of Luxembourg, Wallonia in Belgium, and Lor-
raine in France, Luxembourg ranked first with elevated
cerebro-vascular and ischemic coronary disease mortal-
ity in both men and women[19]. This outcome made
cardiovascular health as one of the top priorities of Lux-
embourg healthcare authorities. Although the Ministry
of health has long been involved in planning and orga-
nizing prevention programs and health promotion cam-
paigns to endorse healthy lifestyles, there has been so
far no proper population-based study to assess the pre-
valence and clustering of cardiovascular risk factors
(CVRF) among adults. Luxembourg is one of the few
European countries without a well-defined structure for
permanent and/or periodic observational surveys on car-
diovascular health statistics.
The “Observation of Cardiovascular Risk Factors in
Luxembourg” (ORISCAV-LUX) survey, was conducted
between November 2007 and January 2009 under the
auspices of the Ministry of Health and co-financed by
the Ministry of Research. It was designed as a nation-
wide cross-sectional cardiovascular monitoring survey
aimed to establish baseline information on the preva-
lence of potentially modifiable and preventable CVRF,
including obesity, hypertension, diabetes mellitus, lipid
disorder, and current smoking, among the general adult
population of Luxembourg. From a public health and
research perspective, this survey is intended to be
repeated at regular intervals to monitor the evolution.
Accurate assessment of the distribution of single and
combined CVRF not only describes the total burden of
CVD but also permits the development of coherent and
effective strategies of prevention and treatment.
Methods
Sampling scheme
A representative random sample was drawn from the
national health insurance registry, stratified by gender
(male and female), age (5-year categories) and districts
of residence (Luxembourg, Diekirch and Grevenmacher).
With a 98% social coverage rate, the registry is consid-
ered as the most complete list of inhabitants available in
Luxembourg. The minimal necessary representative
sample size was calculated to 1285 subjects to ensure
statistical power[20], i.e. to ensure a statistical precision
of at least 2% for the estimation of the prevalence of the
risk factors at the 95% confidence level. However, based
on literature review and previous evidence with such
multiple-stage population-based studies, a high non-par-
ticipation rate was expected, including refusal, invalid
addresses and non-response. Assuming a response rate
of 30% and a proportion of 5% of institutionalized sub-
jects in each stratum, the sample size was augmented to
4496 subjects. The distribution of selected subjects in
each stratum was proportional to their distribution in
t h es o u r c ep o p u l a t i o n( a d u l tp o p u l a t i o no f1 8t o6 9
years residents in Luxembourg). Pregnant women, peo-
ple living in institutions, subjects outside the age range
18-69 years and those deceased before recruitment were
excluded. The sample is weighted to account for the
complex sampling design and for non-response.
Method of recruitment
All selected subjects were invited by an official letter
signed by healthcare authorities and the research centre
for health studies, in which the objectives and the tests
to be performed were broadly explained. They were
asked to send their primary agreement and phone num-
ber by using the prepaid envelope holding the address
of the study research centre. The subjects who agreed to
take part in the study were contacted by phone to
attend the appointment at the nearest medical centre.
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not respond spontaneously after 3 weeks. Participants
were requested to attend the health examination centre
in a fasting state. Home visits were organized in case
the participant had health problems or transport diffi-
culties. An informed consent form was handed to the
participants at their attendance visit and had to be
signed prior to inclusion. The study comprised three
major steps: an auto-administered questionnaire, physi-
cal and anthropometric measurements, and blood, urine
and hair tests. All participants were informed about
their measurements and tests results and were advised
to consult, their family doctor if necessary. Substantial
efforts were made to increase response rate, not only
during the survey preparation but also during the
recruitment phase. Complete details about non-response
management, sample representativeness of the popula-
tion and comparison of participants and non-partici-
pants to ORISCAV-LUX survey are published elsewhere
[21]. Briefly, a total of 1432 subjects (32.2%) were suc-
cessfully recruited, slightly beyond the estimated sample
size and the expected response rate. This analysis
revealed that the distribution between participants and
non-participants was comparable in terms of the cardio-
vascular morbidity indicators, including prescribed med-
ications, hospital admission and medical measures.
Questionnaire
The self-administered questionnaire elicited information
on demographic and socioeconomic characteristics,
including age, gender, country of birth, income, educa-
tion, profession, and marital status. Data regarding life
style characteristics, including cigarette smoking, alcohol
consumption, physical activity and dietary habits, as well
as family and personal diseases history and medication
intake, were also collected. Trained survey nurses helped
and checked the answers with the participants. Given
the multi-linguistic nature of the population residing in
Luxembourg, the self-administered questionnaire was
translated from French into the three other most used
languages, namely German, English and Portuguese, and
then backward translated into French to ensure the
validity [22].
Anthropometric and blood pressure measurements
For blood pressure measurement, subjects were seated
in a chair with their arms bared and supported at heart
level. Systolic blood pressure (SBP, mmHg) and diastolic
blood pressure (DBP, mmHg) were measured at least 3
times with a minimum of 5-min interval between each
measurement, by using Omrom® MX3 plus automated
oscillometric Blood Pressure Monitor (O-HEM-742-E)
(Matsusaka, Japan)[23], with an appropriate cuff size
adapted to the upper arm perimeter of participant.
Measurements were only performed after the partici-
pants had been seated for at least 5 minutes after ques-
tionnaire completion and at least 30 minutes after blood
intake and refrained from smoking. The average of the
last 2 readings was used in the analysis.
Body weight (kg) was recorded with an accuracy
of ± 100 g by using a digital column scale (Seca® 701,
Hamburg, Germany), with subject barefoot and wearing
light clothing. The scale was calibrated regularly. Stand-
ing body height (cm) was recorded to the nearest
0.2 cm with a portable wall stadiometer (Seca, Ger-
many), attached to the scale, with heels together,
shoulders in relaxed position and arms hanging freely.
Body mass index (BMI) was calculated as body weight
in kg divided by the square of height (m). Self-reported
height and weight were not acceptable. Waist circumfer-
ence (WC, cm) was measured at the level midway
between 12th rib and the uppermost lateral border of
the iliac crest during mild expiration. Waist circumfer-
ence was measured to the nearest 0.2 cm with the sub-
ject at standing position, using a flexible, non-distensible
tape and avoiding pressure exertion on the tissues. The
duplicate measurements in a subgroup of participants
showed high reproducibility (data not shown).
Biochemical parameters
A venous blood sample was drawn from the arm of each
subject in sitting position by antecubital vein puncture,
after an overnight 8-hour fast. The blood samples were
transferred to the core Laboratory of the “Centre Hospi-
talier in Luxembourg” (CHL) in tank containing ice
packs to maintain a suitable temperature. They were
centrifuged within maximum 4 hours after extraction
and then immediately analysed. Blood collection tubes
containing glycolytic inhibitors were used for serum glu-
cose test. The Laboratory applies strict internal and
external standard quality control techniques. The
laboratory tests performed included fasting plasma glu-
cose (FPG, mg/dl), triglycerides (TG, mg/dl)), total cho-
lesterol (TC, mg/dl), low-density lipoprotein cholesterol
(LDL-C, mg/dl), high-density lipoprotein Cholesterol
(HDL-C, mg/dl) and other biomarkers.
CVD risk factors
Based on the International Obesity Task Force[24], con-
vened by the World Health Organization, a subject with
BMI ≥ 30.0 kg/m
2 was defined as obese. The WC mea-
surements were used to determine the extent of central
adiposity, with cut-off points of ≥ 102 cm in men and
≥ 88 cm in women[25]. Participants were classified as
having elevated blood pressure if they reported taking
anti-hypertensive medications and/or had SBP ≥ 140
mmHg and/or DBP ≥ 90 mmHg [26].Participants
were classified as diabetics if they reported taking
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[27,28]. Subjects with lipid disorder were defined as hav-
ing at least one of the following anomalies: TC ≥ 190
mg/dl, TG ≥ 150 mg/dl, LDL-C ≥ 115 mg/dl, and HDL-
C < 40 mg/dl for men and < 46 mg/dl for women [29],
and/or taking hypo-lipid medications. Smoking status
was evaluated by the self-reported questionnaire. Each
participant was classified as current smoker, ex-smoker
or non-smoker. Current regular smokers were those
who smoked at least one cigarette per day. Current
occasional smoker were those who smoked less than
one cigarette per day. The present study specifically
focused on 5 distinct CVRF, respectively, obesity, hyper-
tension, diabetes mellitus, lipid disorder, and current
smoking. The metabolic syndrome (MS) was succinctly
presented according to the simplest and most used R-
ATP III definition[30]; a participants is defined as having
the MS when three or more of the following criteria are
met: 1) WC ≥ 102 cm for men and ≥ 88 cm for women;
2) raised concentration of TG ≥ 150 mg/dl or specific
treatment for this lipid anomaly; 3) reduced concentra-
tion of HDL-C < 40 mg/dl for men and < 50 mg/dl for
women or specific treatment for this lipid anomaly; 4)
SBP was ≥ 130 mmHg, or DBP ≥ 85 mmHg or treatment
of previously diagnosed hypertension; 5) FPG level
≥100 mg/dl or use of medication for hyperglycemia.
Quality control procedure
Strict control measures were applied to ensure quality
throughout the conduct of the study, namely, sample
selection, operational data-collection, data processing
and reporting. They included well-defined sampling
design and prior estimation of sample size to reduce
sampling errors; testing and validating the translated
questionnaires; introducing multiple cross-checked
questions on the same topic to validate the results;
training of data collection nurses to perform their duties
according to standard operating procedures; monitoring
and ascertaining of instruments performance every
morning before starting the tests on the subjects; daily
assessment of paper forms for answer’s relevance and
completeness; designing the database in a way that
allows to confirm the validity of the participant’si d e n t i -
fication codes, establishing the completeness of the
entered data and performing basic data checks; training
of data processing personnel to be able to provide reli-
able and accurate documentation, as well as periodic
summary reports on the latest project progress; inde-
pendent double data entry followed by matching and
checking for data-entry errors, so that problems were
appropriately remedied; data cleaning according to
experts consensus; finally, checking of the internal and
external consistency of the analyzed data before
reporting.
Ethical aspects
All participants were duly informed and consented to
take part in the study. The study design and information
collected were approved by the National Research Ethics
Committee and the National Commission for Private
Data Protection.
Statistical analysis
Results were expressed as mean ± SE for quantitative
variables and as count and proportion (%) for categori-
cal variables. Multiple regression analysis was used to
test the effect of age, gender and their interaction on
subject’s quantitative characteristics. Instead, when con-
sidering CVRF binary outcomes, logistic regression was
applied. Given that the present study focused specifically
on 5 CVRF (obesity, hypertension, diabetes mellitus,
lipid disorder, and current smoking), the number of
CVRF was calculated for each subject and analysed as a
discrete variable ranging from 0 (no CVRF) to 5 (all
CVRF present). To account for the stratified random
sampling method used to recruit the subjects, weighted
statistical methods were applied. A sampling weight
equal to the inverse probability of unit selection was
allocated to each subject from the same stratum. This
stratum sampling weight was defined as the ratio
between the population stratum size and the observed
sample stratum size. Results were considered to be sig-
nificant at the 5% critical level (P < 0.05). All statistical
analyses were performed by using the SAS 9.2 (
© SAS
Institute Inc., Cary, NC, USA).
Results
Among the random sample of 4496 subjects aged 18-69
years drawn from Luxembourg residents population,
1432 (697 men and 735 women) responded and were
included in the study. All participants filled out the
questionnaire; however, blood pressure readings were
missing for 2 subjects and anthropometric measure-
ments for one subject. Blood, urine and hair samples
were obtained from, respectively, 1427 (99.7%), 1432
(100%) and 1062 (74.1%) participants.
The anthropometric, clinical and biochemical charac-
teristics of these subjects are displayed in Table 1 by age
category and gender. As expected, mean values of BMI,
WC, SBP, DBP, FPG, TC, LDL-C, and TG increased sig-
nificantly with age; HDL-C levels, however, remained
quite stable across age categories (P = 0.64). A signifi-
cant gender-specific difference was observed for BMI,
W C ,S B P ,F P G ,H D L - C ,L D L - Ca n dT G ,s y s t e m a t i c a l l y
h i g h e ri nm e nt h a ni nw o m e n( P < 0.0001), except for
TC (P = 0.94). For DBP, a significant age-gender inter-
action was found (P = 0.0005), in the sense that DBP
increased more markedly with age in men than in
women.
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prevalences of each of the five CVRF on which the
study focused in addition to the MS. By decreasing pre-
valence, the most predominant cardiovascular risk fac-
tors were lipid disorder (69.9%), hypertension (34.5%),
current smoking (22.3%), obesity (20.9%), and diabetes
(4.4%), respectively. The prevalence of hypertension,
obesity, diabetes mellitus and lipid disorders increased
remarkably with advancing age (P<0.0001). By contrast,
the prevalence of current smoking decreased signifi-
cantly with age (P<0.0001). Further, the prevalence was
significantly higher in men than in women for hyperten-
sion (41.9% vs 27.1%), obesity (23.0% vs 18.7%), lipid
disorders (74.3% vs 65.5%), and current smoking (24.9%
vs 19.7%), as well so for MS (29.5% vs 18.4%), but not
for diabetes (5.2% vs 3.5%, P= 0.08) (data not shown).
No age-gender interaction was found for any of the
CVRF. While the prevalence of hypertension and of
lipid disorders differed significantly by geographic region
of birth, no significant difference was observed for dia-
betes, obesity and current smoking (Table 3).
The distribution of the number of CVRF affecting
each subject is displayed in Figure 1, globally and by
gender. It is seen that 35% of the participants presented
only one CVRF, 29.3% presented 2 CVRF, and 16.9%
presented 3 and more CVRF. Only 18.9% of the subjects
(14.7% of men and 23.1% of women) were free of any
CVRF. Among subjects presenting only one CVRF, 75%
had lipid disorder, 11.4% were regular smokers and 9.5%
suffered hypertension. For individuals with 2 CVRF, the
most frequent combinations were lipid disorder and
hypertension (53%), lipid disorder and smoking (24.2%),
lipid disorder and obesity (14.4%). In subjects with 3
CVRF, the “lipid disorder, hypertension and obesity”
combination was found in 64.9% of the cases, while the
“lipid disorder, hypertension and current smoking” pro-
file was observed in 13.9% of the subjects. Finally, in
subjects with 4 CVRF, it was found that 55.6% of them
were exempt of current smoking and 38.9% were
exempt of diabetes. When analysing the number of
CVRF per participant with respect to age and gender, it
was observed that this number increased significantly
Table 1 Anthropometric, clinical and biochemical characteristics by age category and gender in the ORISCAV-LUX
study
Characteristic 18-29 y 30-39 y 40-49 y 50-59 y 60-69 y P-value* P-value**
Number of subjects (men/women) 221 (106/115) 351 (171/180) 372 (189/183) 284 (135/149) 204 (96/108)
BMI (kg/m
2) Men 24.1 ± 0.3 26.6 ± 0.3 27.7 ± 0.3 28.6 ± 0.4 29.1 ± 0.5 <0.0001 <0.0001
Women 22.9 ± 0.4 25.3 ± 0.3 25.9 ± 0.4 26.6 ± 0.4 29.1 ± 0.6
WC (cm) Men 83.5 ± 1.0 91.6 ± 0.8 96.7 ± 1.0 99.4 ± 1.0 102.0 ± 1.3 <0.0001 <0.0001
Women 76.6 ± 1.0 83.1 ± 0.9 84.3 ± 0.9 87.7 ± 1.0 93.8 ± 1.4
SBP (mmHg) Men 124.3 ± 1.1 127.5 ± 1.0 134.0 ± 1.1 139.5 ± 1.3 149.7 ± 1.9 <0.0001 <0.0001
Women 114.8 ± 0.8 116.9 ± 0.9 124.0 ± 1.1 131.8 ± 1.3 142.8 ± 2.0
DBP (mmHg) Men 74.1 ± 0.7 81.9 ± 0.8 87.1 ± 0.8 88.2 ± 0.8 88.5 ± 1.2 <0.0001
$ 0.26
$
Women 74.8 ± 0.8 77.1 ± 0.8 81.2 ± 0.8 83.7 ± 0.8 84.3 ± 1.1
FPG (mg/dl) Men 89.6 ± 1.0 91.9 ±0.7 97.7 ± 0.9 106.2 ± 2.3 108.5 ± 2.7 <0.0001 <0.0001
Women 84.4 ± 0.6 86.8 ± 0.6 92.2 ± 0.9 96.3 ± 1.8 99.9 ± 2.4
TC (mg/dl) Men 170.5 ± 3.4 198.3 ± 2.9 214.5 ± 2.9 210.1 ± 3.2 198.9 ± 4.2 <0.0001 0.94
Women 177.7 ± 3.3 189.9 ± 2.9 199.1 ± 2.5 220.3 ±2.7 217.1 ± 4.5
HDL-C (mg/dl) Men 53.9 ± 1.2 53.2 ± 0.9 53.1 ± 1.1 53.9 ± 1.2 54.7 ± 1.5 0.64 <0.0001
Women 68.4 ± 1.4 67.9 ± 1.2 67.6 ± 1.2 69.1 ± 1.5 69.4 ± 2.0
LDL-C (mg/dl) Men 104.1 ± 2.9 126.1 ± 2.3 140.1 ± 2.6 137.0 ± 2.8 127.8 ± 3.9 <0.0001 <0.0001
Women 98.2 ± 2.8 109.9 ± 2.3 119.5 ± 2.2 135.5 ± 2.5 132.4 ± 4.0
TG (mg/dl) Men 95.4 ± 6.5 138.9 ± 11.2 149.3 ± 7.5 140.5 ± 6.5 134.4 ± 6.0 <0.0001 <0.0001
Women 85.8 ± 3.8 97.8 ± 11.5 89.6 ± 3.6 105.7 ± 5.1 107.7 ± 5.6
Results are expressed as Mean ± SE. * P-value for age, ** P-value for gender, $ adjusted for age and sex interaction when necessary
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m e nt h a ni nw o m e n( P < 0.0001). The interaction term
between age and gender was not significant.
Figure 2 illustrates the prevalence of treated and non-
treated participants with hypertension, diabetes and lipid
disorder. The prevalence of hypertension among the
resident population was 34.5%; about two thirds of the
participants (22.1%) were not treated. Among the 4.4%
participants having the diabetes, 2.8% were treated
against 1.5% non-treated. Among those with lipid disor-
der (69.9%), only 9.2% were under medication.
Discussion
In Grand-Duchy of Luxembourg, CVD is the primary
cause of mortality and a major reason for hospital
admission. This has led public health authorities to
consider CVD as one of their national healthcare prio-
rities. It is well established that early management of
CVRF by lifestyle modifications and/or therapeutic
interventions leads to marked reduction in mortality,
morbidity, and maintaining quality of life [31,32].
Therefore, early detection of individuals with modifi-
able and treatable CVRF may result in saving lives and
reducing the burden on healthcare resources. In the
absence of relevant national baseline statistics, the
observation of CVRF by national periodic surveys is an
essential tool to formulate coherent and effective stra-
tegies of prevention.
This paper describes the rationale, the objectives, the
method of recruitment and the primary outcomes of the
ORISCAV-LUX study, the first national large-scale
epidemiological survey with a representative sample of
18-69 years old adults residing in Luxembourg. Our
findings indicate that several CVRF are highly prevalent
Table 2 Prevalence of cardiovascular risk factors (CVRF) by age category and gender in the ORISCAV-LUX study
CVRF 18-69
n (%)
18-29
n (%)
30-39
n (%)
40-49
n (%)
50-59
n (%)
60-69
n (%)
P-value* P-value**
Obesity Total 325 (20.9)
Men 175 (23) 7 (6.3) 35 (20.3) 50 (26.6) 45 (32.9) 38 38.6) <0.0001 0.03
Women 150 (18.7) 7 (6.7) 28 14.2) 40 (20.6) 32 (22.2) 43 (39.4)
Hypertension Total 540 (34.5)
Men 322 (41.9) 10 (9.3) 50 (28.7) 95 (50.2) 86 (63.0) 81 (84.1) <0.0001 <0.0001
Women 218 (27.1) 7 (6.3) 22 (13.1) 51 (26.7) 64 (43.5) 74 (67.8)
Diabetes Total 69 (4.4)
Men 39 (5.2) 1 (1.1) 1 (0.7) 7 (3.8) 12 (8.8) 18 (18.8) <0.0001 0.08
Women 30 (3.5%) 0 (-) 1 (0.5) 5 (2.4) 8 (5.3) 16 (14.7)
Lipid disorder Total 1033 (69.9)
Men 533 (74.3) 44 (42.7) 119 (70.9) 159 (84.5) 120 (89.7) 91 (96.5) <0.0001 0.0002
Women 500 (65.5) 48 (42.3) 93 (52.0) 124 (67.8) 136 (92.0) 99 (92.0)
Current smoking Total 307 (22.3)
Men 165 (24.9) 41 (38.6) 39 (22.7) 46 (24.5) 30 (22.4) 9 (8.6) <0.0001 0.03
Women 142 (19.7) 33 (28.7) 32 (17.3) 31 (16.7) 31 (20.3) 15 (13.0)
R-ATPIII-defined MS Total 368 (24.0) 9 (4.4) 40 (11.6) 95 (25.5) 114 (42.1) 110 (55.1) <0.0001 <0.0001
Men 221 (29.5) 7 (6.9) 26 (15.6) 62 (33.8) 67 (50.5) 59 (61.2)
Women 147 (18.4) 2 (2.0) 14 (7.5) 33 (17.1) 47 (33.3) 51 (49.4)
Results are expressed as number of cases (%). * P value for age, ** P-value for gender
Table 3 Prevalence of CVRF by geographic region of
birth adjusted for age, gender and district
CVRF Luxembourg
(n = 869)
Portugal
(n =
169)
Europe
(n =
311)
Others
(n = 83)
P-
value
Obesity 21.5% ± 1.3 23.6% ±
3.2
18.4% ±
2.2
17.7% ±
4.2
0.45
Hypertension 37.1% ± 1.5 37.6% ±
3.7
28.1% ±
2.5
25.4% ±
4.7
0.009
Diabetes 4.7% ± 0.7 3.1% ±
1.3
4.7% ±
1.1
2.1% ±
1.4
0.51
Lipid disorder 70.5% ± 1.6 68.3% ±
3.8
73.3% ±
5.8
56.3% ±
2.6
0.039
Current
smoking
23.1% ± 1.5 21.4% ±
3.4
21.1% ±
2.4
20.4% ±
4.7
0.86
Results are expressed as percents ± SE
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tension, smoking, obesity, and diabetes. The great varia-
tions in published data make direct international
comparisons exceedingly difficult, not only because of
important methodological differences with respect to
the characteristics of the target population, the study
design, the sample selection, and the year of conduct,
but also due to the multifactorial origin of this health
problem and the particularity of health systems. Glob-
ally, high CVRF prevalence rates were reported in indus-
trialized countries. According to the most recent
statistics from Canada, 26% of Canadians were current
smokers, 14.9% were obese, 13.0% had hypertension and
4.2% had diabetes [33].
Figure 1 Distribution of the number of CVRF per subject globally and by gender in the ORISCAV-LUX study.
Figure 2 Prevalence of treated and non-treated participants with hypertension, diabetes and lipid disorder in the ORISCAV-LUX study.
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women for all conditions, except for diabetes. Interest-
ingly, the gender-specific prevalence rates found in the
ORISCAV-LUX study were consistent with previously
reported findings in European countries, such as Italy
[34], Spain[35], Switzerland [36] and Sweden[37].
According to ORISCAV-LUX findings, lipid disorder
was the most prominent risk factor for both genders
and in all age categories. This observation should never-
theless be interpreted with precaution, in particular by
bearing in mind the very strict thresholds regarding the
prophylactic medication of subjects who would other-
wise be considered formerly at lower risk. Although the
variety of definitions complicates comparison with pre-
vious studies of adult populations, these percentages are
among the highest reported in the literature and might
also explain the higher prevalence of obesity. The high
prevalence of dyslipidemia calls for an early screening of
lipid disorders and for an evaluation of current national
nutritional recommendations.
In the present study, there was no significant differ-
ence in the prevalence of diabetes between men and
women. However, the frequency of the disease increased
with age. Although this finding was consistent with that
of Switzerland study [36], the overall recorded diabetes
rate was lower in Luxembourg (4.4% against 6.6%,
respectively).
In USA, smoking is the leading preventable cause of
death[38]. Despite the difficulty to compare tobacco
consumption on international level, the overall age-
adjusted prevalence of smoking in 21 European coun-
tries was 33.1% in men and 29% in women, with major
variations between country samples[39]. In the ORIS-
CAV-LUX survey, about a quarter of the participants
were current (occasional and regular) smokers. Globally,
the prevalence of smoking was significantly higher in
men than in women and decreased with age. Interest-
ingly, these findings were comparable to those of the
national tobacco consumption survey, carried out
annually by the national foundation of fight against can-
cer. The increasing awareness of the damaging health
effects of smoking, together with the anti-smoking mea-
sures of the government, including intensified anti-
smoking campaigns, the banning of advertising and
taxation, contributed widely to the declining trend of
smoking among adults over the last two decades. From
a public health point of view, it is important to maintain
this progression since 54% of world ischemic heart dis-
eases and 25% of world cardiovascular mortality cases
were attributed to smoking[40].
Luxembourg is characterized by its multicultural nat-
ure. Among Europeans, the Portuguese represent the
largest segment of the population. The preliminary
ORISCAV-LUX findings showed that the prevalence of
two CVRF studied, specifically the hypertension and
lipid disorders, differed significantly between countries
of birth (Luxembourg, Portugal, Europe and others).
Characterising groups at risk in the general population
is important to enable tailoring public health action
accordingly. However, this issue needs further research
to support the hypothesis that the risk of CVD is influ-
enced by the country of birth and that immigrants tend
to have better health[41].
It has been recognized that CVRF are associated with
each other and their effects tend to be synergistic rather
than additive[5,42,43]. Thus, the assessment of multiple
risk factors is crucial to identify a high risk population.
The metabolic syndrome is the most suggested
approach to study the clustering of CVRF in a popula-
tion. The overall prevalence of MS, estimated according
to R-ATP III criteria, was 24% among the participants
aged 18-69 years residing in Luxembourg. In scope of
the present manuscript, the focus was primarily on the
number of CVRF per individual. Further data on the
metabolic syndrome will be published separately. Inter-
estingly, it was found that combinations of two or more
CVRF were more frequently observed in men than in
women and increased remarkably with age. Moreover,
multiple risk profiles already emerged within the young
adults aged 18-29 years (data not shown). These find-
ings suggest that cumulated CVRF is quite common in
the Luxembourg’s apparently healthy adult population
and appears to be already present in young men and to
persist thereafter. These observations were consistent
with results from previous recent studies[44,36,45]. High
prevalence of non-treated CVRF, notably of the hyper-
tension and dyslipidemia were observed in the study
population. Although further in-depth analysis is neces-
sary, these preliminary findings underline the necessity
to increase disease awareness, to improve screening of
high risk subjects and to promote prevention both at
the public and individual levels.
T h es t r e n g t h so ft h eO R I S C A V - L U Xs t u d yr e s i d e
firstly in the population sample; the small size of the
country made it possible to organize data collection at a
national level. Secondly, a complementary study com-
paring the known demographic and cardiovascular
health-related profiles of participants and non-partici-
pants demonstrated that the participants did not differ
substantially from non participants. Given the absence
of discriminating health profiles between participants
and non-participants, it was concluded that the response
rate did not invalidate the results and allowed generaliz-
ing the findings for the entire population (detailed
results on this comparison are published separately).
Thirdly, the conception of the survey was consistent
with the WHO stepwise approach[46], which recom-
mends measuring chronic diseases risk factors by using
Alkerwi et al. BMC Public Health 2010, 10:468
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Page 8 of 10standardized tools and objective measurements to facili-
tate national and international comparability. To avoid
inaccurate retrieving of CVRF from self-administered
information, this approach permits to provide reliable
objective estimates of the prevalence of major CVRF,
n a m e l y ,o b e s i t y ,d i a b e t e s, hypertension and lipid
disorders.
Perspectives
Further analyses of the ORISCAV-LUX database are
currently ongoing. In particular, the assessment of the
prevalence of the metabolic syndrome and its associated
socioeconomic determinants, as well as its interaction
with dietary habits, alcohol consumption and physical
activity are important topics to be studied in more
detail. A continuous monitoring of the CVRF with
clearly specified research and public health objectives is
planned to study their trends over time.
Conclusion
According to the current guidelines, the ORISCAV-LUX
survey documents for the first time a remarkably high
prevalence of major CVRF among the adult residents in
Luxembourg. In addition, the survey data confirm signif-
icant age-gender differences as well as individual CVRF
p r o f i l e s .T h ep r e s e n c eo f2o rm o r eC V R Fp e rs u b j e c t
w a sm o r ep r e d o m i n a n ti nm e nt h a ni nw o m e n ,w h i l e
the younger age group (18-29 years) already presented a
striking multiple risk profile.
The ORISCAV-LUX survey constituted a timely
opportunity to identify public health determinants,
hence to help shaping policies according to preventive
needs of the population. Its first outcomes underscore
the need to identify other characteristics of high-risk
population, to continue epidemiological monitoring and
to implement population-based multiple-facet interven-
tions tailored for special groups at risk.
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